ResMed (RMD) Tops Q2 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2019
January 24, 2019 4:05 PM ESTYear-over-year growth in revenue, gross margin, and operating profit Well-positioned for future growth through further penetration of untreated sleep apnea and expanding portfolio in respiratory care and Software as a Service
Note: A webcast of ResMeds conference call will be available at 4:30 p.m. EST today at http://investor.resmed.com
SAN DIEGO--(BUSINESS WIRE)-- ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading connected... More
